Valuation: UBI Pharma Inc.

Market Cap 168.32Cr 5.22Cr 4.52Cr 4.24Cr 3.86Cr 7.27Cr 497.91Cr 7.39Cr 50Cr 19Cr 249.22Cr 20Cr 19Cr 831.44Cr P/E 2024
-9.63x
P/E 2025 -5.68x
Enterprise Value 197.21Cr 6.12Cr 5.3Cr 4.96Cr 4.53Cr 8.52Cr 583.37Cr 8.66Cr 58Cr 23Cr 291.99Cr 23Cr 22Cr 974.14Cr EV / Sales 2024
3.58x
EV / Sales 2025 3.83x
Free-Float
27.79%
Yield 2024 *
-
Yield 2025 -
3 years 10
Extreme 10
38.5
5 years 10
Extreme 10
199.22
10 years 8.34
Extreme 8.341363
288.72
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 11/04/2016
Chief Administrative Officer - 01/03/2015
Director TitleAgeSince
Director/Board Member - 30/06/2020
Director/Board Member - 30/06/2020
Director/Board Member - 30/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-.--%-.--%-57.88% 5.22Cr
-0.75%+9.65%+92.58%+131.57% 1,09800Cr
-1.24%+1.58%+48.98%+48.96% 63TCr
+0.01%+1.72%+24.85%+62.96% 44TCr
-1.13%+3.13%+49.78%+39.13% 37TCr
-0.74%+1.01%+31.08%+38.64% 30TCr
-1.22%+0.89%+7.32%+7.38% 25TCr
-0.87%+6.03%+45.06%+57.53% 23TCr
+0.34%-0.13%-4.77%-50.50% 21TCr
+1.60%-0.12%+12.14%+68.86% 16TCr
Average -0.17%+1,491.93%+30.70%+34.67% 36.84TCr
Weighted average by Cap. -0.61%+1,331.48%+49.95%+66.36%

Financials

2024 2025
Net sales 54Cr 1.67Cr 1.45Cr 1.36Cr 1.24Cr 2.33Cr 159.39Cr 2.37Cr 16Cr 6.23Cr 80Cr 6.27Cr 6.14Cr 266.16Cr 51Cr 1.6Cr 1.38Cr 1.29Cr 1.18Cr 2.22Cr 152.18Cr 2.26Cr 15Cr 5.95Cr 76Cr 5.99Cr 5.86Cr 254.11Cr
Net income -17Cr -54.13L -46.9L -43.91L -40.07L -75.4L -52Cr -76.66L -5.15Cr -2.02Cr -26Cr -2.03Cr -1.99Cr -86Cr -30Cr -91.89L -79.63L -74.55L -68.02L -1.28Cr -88Cr -1.3Cr -8.74Cr -3.42Cr -44Cr -3.45Cr -3.38Cr -146.35Cr
Net Debt 25Cr 76.4L 66.21L 61.99L 56.56L 1.06Cr 73Cr 1.08Cr 7.27Cr 2.85Cr 36Cr 2.87Cr 2.81Cr 121.69Cr 29Cr 89.6L 77.65L 72.69L 66.32L 1.25Cr 85Cr 1.27Cr 8.52Cr 3.34Cr 43Cr 3.36Cr 3.29Cr 142.7Cr
Logo UBI Pharma Inc.
Ubi Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services.
Employees
-
  1. Stock Market
  2. Stocks
  3. 6562 Stock